Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

NCT02629393 is registered in ClinicalTrials.gov with Origin Biosciences as lead sponsor.

NCT NCT02629393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02629393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A
Lead sponsor
Origin Biosciences
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2016
Completion date
October 31, 2022
Enrollment
5 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

molybdenum cofactor deficiency, type a